ROCKVILLE, Md., May 03, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that President and CEO Kenneth T. Mills will participate in the following May investor conferences.
Bank of America Merrill Lynch 2016 Health Care Conference
Dates: Tuesday, May 10 – Thursday, May 12
Location: Encore at Wynn, Las Vegas
Company presentation: Tuesday, May 10 at 2:20 - 2:50 p.m. PDT
Piper Jaffray GenomeRx Symposium
Date: Tuesday, May 17
Location: The InterContinental New York Barclay, New York City
Panels: Vectors & Promoters Pointing the Way, 9:10 - 9:45 a.m. EDT
Thinking Smart About CNS Targeting Gene Therapy, 11:20 - 11:55 a.m. EDT
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of AAV gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of December 31, 2015, REGENXBIO's NAV Technology Platform is being applied in the development of 28 product candidates for a variety of diseases, including five internally developed candidates and 23 partnered candidates developed by REGENXBIO's licensees.